| pubmed-article:21427706 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C0032868 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C1516119 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C1518581 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C1709630 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:21427706 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:21427706 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21427706 | pubmed:dateCreated | 2011-6-1 | lld:pubmed |
| pubmed-article:21427706 | pubmed:abstractText | JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In a phase 1 trial, JX-594 injection into hepatocellular carcinoma (HCC) was well-tolerated and associated with viral replication, decreased tumor perfusion, and tumor necrosis. We hypothesized that JX-594 and sorafenib, a small molecule inhibitor of B-raf and vascular endothelial growth factor receptor (VEGFR) approved for HCC, would have clinical benefit in combination given their demonstrated efficacy in HCC patients and their complementary mechanisms-of-action. HCC cell lines were uniformly sensitive to JX-594. Anti-raf kinase effects of concurrent sorafenib inhibited JX-594 replication in vitro, whereas sequential therapy was superior to either agent alone in murine tumor models. We therefore explored pilot safety and efficacy of JX-594 followed by sorafenib in three HCC patients. In all three patients, sequential treatment was (i) well-tolerated, (ii) associated with significantly decreased tumor perfusion, and (iii) associated with objective tumor responses (Choi criteria; up to 100% necrosis). HCC historical control patients on sorafenib alone at the same institutions had no objective tumor responses (0 of 15). Treatment of HCC with JX-594 followed by sorafenib has antitumoral activity, and JX-594 may sensitize tumors to subsequent therapy with VEGF/VEGFR inhibitors. | lld:pubmed |
| pubmed-article:21427706 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21427706 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21427706 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21427706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21427706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21427706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21427706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21427706 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21427706 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21427706 | pubmed:issn | 1525-0024 | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:KimMi KyungMK | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:KirnDavid HDH | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:HwangTae-HoTH | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:KimChang... | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:OhSung YongSY | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:HeoJeongJ | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:BellJohn CJC | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:WooHyun... | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:FallsTheresaT | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:ParatoKelleyK | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:MoonAnneA | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:BreitbachCaro... | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:RintoulJuliaJ | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:PattRickR | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:LeeYu KyungYK | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:HickmanTheres... | lld:pubmed |
| pubmed-article:21427706 | pubmed:author | pubmed-author:RheeByung-Geo... | lld:pubmed |
| pubmed-article:21427706 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21427706 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:21427706 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21427706 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21427706 | pubmed:pagination | 1170-9 | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:meshHeading | pubmed-meshheading:21427706... | lld:pubmed |
| pubmed-article:21427706 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21427706 | pubmed:articleTitle | Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. | lld:pubmed |
| pubmed-article:21427706 | pubmed:affiliation | Pusan National University, Busan, South Korea. | lld:pubmed |
| pubmed-article:21427706 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21427706 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
